US FDA approval for Quo-Test analyser

 20th Feb 2019

Download the full announcement

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.

 

The Quo-Test is a fully automated glycated haemoglobin (HbA1c) analyser, providing fast, easy and reliable HbA1c measurement for the monitoring and management of diabetes.

 

The FDA 510(k) clearance allows the Quo-Test to be used in a laboratory setting for in-vitro quantitative determination of HbA1c in whole blood samples. 

 

For more information on the Quo-Test see: https://www.ekfdiagnostics.com/quo-test.html

 

Commenting, Julian Baines, CEO of EKF, said:

“We are very pleased with the FDA approval of Quo-Test as this increases the portfolio of products that can now be marketed in the US.”

 

Enquiries:

EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, Finance Director and COO

www.ekfdiagnostics.com
Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker)

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)
Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303